ABX-CRO advanced pharmaceutical services Forschungsgesellschaft m.b.H.   Report issue

For profit Phase 3
Founded: Dresden Germany (2002)

Organization Overview

First Clinical Trial
2020
NCT04261777
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

ABX-CRO advanced pharmaceutical services Forschungsgesellschaft m.b.H.

Active Ingredients

Drugs in Phase 3 Trials (1)

iron oxide (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Prostatic Neoplasms (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 1
  • # of Trial APIs: 1